Simplex Trading’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $113K | Sell |
81,100
-61,200
| -43% | -$84.1K | ﹤0.01% | 4944 |
|
|
2025
Q4 | $229K | Sell |
142,300
-4,100
| -3% | -$8.59K | ﹤0.01% | 4087 |
|
|
2025
Q3 | $399K | Buy |
146,400
+41,200
| +39% | +$137K | ﹤0.01% | 4112 |
|
|
2025
Q2 | $382K | Buy |
105,200
+99,500
| +1,746% | +$273K | ﹤0.01% | 3797 |
|
|
2025
Q1 | $10K | Sell |
5,700
-41,800
| -88% | -$85.3K | ﹤0.01% | 7067 |
|
|
2024
Q4 | $90K | Sell |
47,500
-239,400
| -83% | -$416K | ﹤0.01% | 5274 |
|
|
2024
Q3 | $378K | Sell |
286,900
-42,900
| -13% | -$57.3K | ﹤0.01% | 3882 |
|
|
2024
Q2 | $336K | Buy |
329,800
+5,500
| +2% | +$6.8K | ﹤0.01% | 4096 |
|
|
2024
Q1 | $593K | Buy |
324,300
+167,500
| +107% | +$268K | ﹤0.01% | 3679 |
|
|
2023
Q4 | $194K | Sell |
156,800
-162,000
| -51% | -$165K | ﹤0.01% | 4709 |
|
|
2023
Q3 | $363K | Buy |
318,800
+36,200
| +13% | +$46.5K | ﹤0.01% | 3731 |
|
|
2023
Q2 | $258K | Sell |
282,600
-41,900
| -13% | -$40.4K | ﹤0.01% | 4013 |
|
|
2023
Q1 | $181K | Sell |
324,500
-115,500
| -26% | -$88.2K | ﹤0.01% | 4443 |
|
|
2022
Q4 | $253K | Sell |
440,000
-97,200
| -18% | -$30.5K | ﹤0.01% | 3931 |
|
|
2022
Q3 | $169K | Buy |
537,200
+311,600
| +138% | +$122K | ﹤0.01% | 4839 |
|
|
2022
Q2 | $79K | Sell |
225,600
-280,800
| -55% | -$118K | ﹤0.01% | 5880 |
|
|
2022
Q1 | $363K | Buy |
506,400
+460,800
| +1,011% | +$986K | ﹤0.01% | 4278 |
|
|
2021
Q4 | $103K | Sell |
45,600
-9,000
| -16% | -$24.5K | ﹤0.01% | 6197 |
|
|
2021
Q3 | $211K | Buy |
54,600
+200
| +0.4% | +$571 | ﹤0.01% | 5506 |
|
|
2021
Q2 | $206K | Buy |
54,400
+53,839
| +9,597% | +$181K | ﹤0.01% | 5636 |
|
|
2021
Q1 | $189K | Buy |
561
+128
| +30% | +$461 | ﹤0.01% | 4824 |
|
|
2020
Q4 | $121K | Sell |
433
-8
| -2% | -$23 | ﹤0.01% | 5240 |
|
|
2020
Q3 | $110K | Buy |
441
+210
| +91% | +$1.84K | ﹤0.01% | 4802 |
|
|
2020
Q2 | $313K | Buy |
231
+189
| +450% | +$1.96K | ﹤0.01% | 3472 |
|
|
2020
Q1 | $31K | Sell |
42
-70
| -63% | -$545 | ﹤0.01% | 5581 |
|
|
2019
Q4 | $70K | Buy |
112
+64
| +133% | +$304 | ﹤0.01% | 4874 |
|
|
2019
Q3 | $18K | Sell |
48
-20
| -29% | -$86 | ﹤0.01% | 5870 |
|
|
2019
Q2 | $32K | Sell |
68
-135
| -67% | -$768 | ﹤0.01% | 5214 |
|
|
2019
Q1 | $165K | Hold |
203
| – | – | ﹤0.01% | 3806 |
|
|
2018
Q4 | $112K | Buy |
203
+111
| +121% | +$869 | ﹤0.01% | 3757 |
|
|
2018
Q3 | $81K | Buy |
92
+30
| +48% | +$268 | ﹤0.01% | 4649 |
|
|
2018
Q2 | $61K | Buy |
+62
| New | +$621 | ﹤0.01% | 4830 |
|
|
2017
Q4 | – | Sell |
-21
| Closed | -$11K | – | 5902 |
|
|
2017
Q3 | $11K | Sell |
21
-103
| -83% | -$1.58K | ﹤0.01% | 3661 |
|
|
2017
Q2 | $35K | Buy |
124
+119
| +2,380% | +$1.51K | ﹤0.01% | 2710 |
|
|
2017
Q1 | $1K | Sell |
5
-10
| -67% | -$98 | ﹤0.01% | 5521 |
|
|
2016
Q4 | $4K | Buy |
+15
| New | +$129 | ﹤0.01% | 4486 |
|
|
2016
Q3 | – | Sell |
-57
| Closed | -$5K | – | 5711 |
|
|
2016
Q2 | $5K | Sell |
57
-12
| -17% | -$105 | ﹤0.01% | 4203 |
|
|
2016
Q1 | $6K | Buy |
69
+10
| +17% | +$81 | ﹤0.01% | 3893 |
|
|
2015
Q4 | $45K | Sell |
59
-178
| -75% | -$1.82K | ﹤0.01% | 1991 |
|
|
2015
Q3 | $15K | Buy |
237
+27
| +13% | +$248 | ﹤0.01% | 3050 |
|
|
2015
Q2 | $22K | Buy |
210
+201
| +2,233% | +$1.72K | ﹤0.01% | 2362 |
|
|
2015
Q1 | $3K | Buy |
+9
| New | +$96 | ﹤0.01% | 3794 |
|
Other funds holding AKBA
VCM
VPM
Simplex Trading's AKBA Position: Q1 2026 in Review
Simplex Trading reduced its Akebia Therapeutics (AKBA) stake by 49% in Q1 2026, selling an estimated $14.2K and leaving 10,589 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7011.
Simplex Trading first reported a position in AKBA in Q3 2015 and has held it in 30 quarters since. The position peaked at $883K in Q1 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Simplex Trading held 10,589 shares of Akebia Therapeutics worth $14.7K as of Q1 2026.
- Simplex Trading sold 10,306 Akebia Therapeutics shares in Q1 2026, an estimated $14.2K.
- Akebia Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7011 holding.
- Simplex Trading first reported a position in Akebia Therapeutics in Q3 2015 and has held it in 30 quarters since.
- Simplex Trading's Akebia Therapeutics position peaked at $883K in Q1 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.